Insights

AnteoTech (ASX:ADO) share price soars 7% on news of rapid COVID-19 test

Shares in the biotech company are gaining today following an update on its rapid diagnostic test
The post AnteoTech (ASX:ADO) share price soars 7% on news of rapid COVID-19 test appeared first on The Motley Fool Australia. –

The AnteoTech Ltd (ASX: ADO) share price is rocketing today. This comes after news the company has submitted its SARS-CoV-2 antigen rapid diagnostic test for Therapeutic Goods Administration (TGA) approval.

According to the company, its rapid diagnostic test is able to detect COVID-19 in 97.3% of cases and can provide results in 1 minute.  

At the time of writing, the AnteoTech share price is 29.5 cents, 7.27% higher than its previous close.

Let’s take a closer look at today’s news from the biotechnology company.

Rapid COVID-19 test submitted for TGA approval

The AnteoTech share price is soaring after the company announced it has submitted its COVID-19 rapid diagnostic test for TGA approval.

AnteoTech’s test uses a nasal swap to test for COVID-19 infections in 1 minute. AnteoTech is also working on creating a saliva-based sampling method.

The test has been submitted for TGA approval alongside AnteoTech’s Eugeni Reader Platform – a transportable device needed to read AnteoTech’s rapid COVID-19 tests.

If the products receive TGA approval, AnteoTech will begin marketing, selling, and using the tests in Australia.

AnteoTech is already working with Australian distributor, Abacus dx, in the hope the rapid testing products will be approved.

Abacus has a strong pipeline of potential customers for the test across the healthcare and screening markets. AnteoTech believes the test’s first sales will happen shortly after it’s listed on the Australian Register of Therapeutic Goods.

The AnteoTech share price soared 14% last week when the company announced a distribution agreement to sell the rapid tests in Greece and Cyprus.

Additionally, if the TGA grants approval for the rapid test, it will create a benchmark for its efficacy and quality.

Currently, numerous COVID-19 rapid diagnostic tests are approved for use in Australia.

However, the TGA advises rapid diagnostic tests for COVID-19 shouldn’t be relied upon. The body says the prevalence of COVID-19 in Australia is lower than the number of false positives or false negatives that would likely result from rapid testing.

AnteoTech share price snapshot

Today’s gains included, the AnteoTech share price is 168% higher than it was at the start of 2021.

It has also gained 268% since this time last year.

The post AnteoTech (ASX:ADO) share price soars 7% on news of rapid COVID-19 test appeared first on The Motley Fool Australia.

Should you invest $1,000 in AnteoTech right now?

Before you consider AnteoTech, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and AnteoTech wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Afterpay, AnteoTech, Cettire, & Vulcan shares are storming higher

These 3 ASX Healthcare shares have surged over 10% today

Why the AnteoTech (ASX:ADO) share price is advancing 9% today
Why Anteotech, API, Myer, & Whitehaven Coal shares are charging higher

Why AnteoTech, BlueBet, Flight Centre, & Mosaic Brands are racing higher

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!